Study guide

8.3 Psychotic Disorders & Schizophrenia Management

Medical Council of Canada Qualifying Examination Part I MCCQE Part I

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice

1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics

2 Chapter 2: Population Health, Health Promotion & Preventive Care

2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada

3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems

3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions

4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology

4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers

5 Chapter 5: General Surgery, Orthopedics, & Emergency Care

5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition

6 Chapter 6: Pediatrics & Adolescent Health

6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management

7 Chapter 7: Obstetrics & Gynecology

7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation

8 Chapter 8: Psychiatry & Mental Health

8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)

9 Chapter 9: Neurology, Rheumatology, & Dermatology

9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine

10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice

10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety

8.3 Psychotic Disorders & Schizophrenia Management

Key Takeaways Explain This Topic AI

Schizophrenia diagnosis requires symptoms persisting for >6 months (with >=1 month of active phase symptoms: delusions, hallucinations, or disorganized speech) causing functional decline.

Second-generation atypical antipsychotics (SGAs) are first-line for schizophrenia due to lower risk of extrapyramidal symptoms (EPS), but require regular monitoring for metabolic syndrome (weight, glucose, lipid panel).

Clozapine is the gold standard for treatment-resistant schizophrenia (failed >=2 antipsychotic trials) but requires strict ANC monitoring via the Canadian Clozapine Network due to the risk of agranulocytosis (stop if ANC <1.0 x 10^9/L).

Neuroleptic Malignant Syndrome (NMS) presents with fever, 'lead-pipe' rigidity, autonomic instability, and elevated creatine kinase; management requires immediate antipsychotic cessation, aggressive cooling, and dantrolene or bromocriptine.

Acute dystonic reactions (e.g., torticollis, oculogyric crisis) occur rapidly after starting high-potency typical antipsychotics and are treated immediately with IM anticholinergics (benztropine or diphenhydramine).

Last updated: July 2026

8.3 Psychotic Disorders & Schizophrenia Management

Psychotic disorders are characterized by abnormalities in one or more of five domains: delusions, hallucinations, disorganized thinking (speech), grossly disorganized or abnormal motor behavior (including catatonia), and negative symptoms. Prompt recognition, medical workup, and intervention are vital to optimize long-term cognitive and functional trajectories.

Spectrum of Psychotic Disorders

The psychotic spectrum is classified primarily by symptom duration and the relationship between psychotic and mood symptoms. Duration & Diagnostic Continuum:

  • Brief Psychotic Disorder: < 1 month (Full recovery)
  • Schizophreniform Disorder: 1 month to 6 months
  • Schizophrenia: > 6 months (Continuous signs of disturbance, including functional decline)
  • Schizoaffective Disorder vs. Mood Disorder with Psychotic Features

Schizoaffective Disorder: Major mood episode (depressive or manic) concurrent with active phase symptoms of schizophrenia, PLUS delusions or hallucinations for ≥ 2 \ge 2 ≥ 2 weeks in the absence of a major mood episode .

Major Depressive / Bipolar Disorder with Psychotic Features: Psychotic symptoms occur exclusively during an active mood episode (manic or depressed).

Schizophrenia: Clinical Presentation & Pathophysiology

Schizophrenia affects approximately 1% of the Canadian population, typically emerging in late adolescence or early adulthood.

Symptom Domains

Positive Symptoms: Excess or distortion of normal function driven by hyperdopaminergic activity in the mesolimbic pathway .

Delusions: Fixed, false beliefs impervious to contrary evidence (persecutory, referential, somatic, grandiose).

Hallucinations: Perception without external stimulus (auditory hallucinations are most common).

Disorganized Speech/Thinking: Derailment, loose associations, word salad, neologisms.

Negative Symptoms: Loss or diminution of normal function driven by hypodopaminergic activity in the mesocortical pathway .

The 5 A's: A volition (lack of motivation), A logia (poverty of speech), A nhedonia, A ffective flattening, A sociality.

Cognitive Symptoms: Deficits in executive function, working memory, and sustained attention.

Pharmacotherapy: First- vs. Second-Generation Antipsychotics

Antipsychotic medications form the mainstay of schizophrenia treatment.

Class Receptor Profile Key Examples Primary Clinical Advantage Major Adverse Effects & Risks

First-Generation (Typical / FGA) Potent Dopamine D2 Receptor Antagonists Haloperidol, Fluphenazine, Chlorpromazine Effective for positive symptoms; low cost High risk of EPS (dystonia, akathisia, parkinsonism, tardive dyskinesia), hyperprolactinemia, QT prolongation.

Second-Generation (Atypical / SGA) D2 Antagonism + 5-HT2A Receptor Blockade Risperidone, Olanzapine, Quetiapine, Aripiprazole, Ziprasidone Lower EPS risk; superior for negative symptoms & cognition Metabolic Syndrome (weight gain, dyslipidemia, insulin resistance/diabetes). Olanzapine and Clozapine carry highest metabolic risk.

Clozapine in Treatment-Resistant Schizophrenia (TRS)

Clozapine is the most effective antipsychotic agent available and is the gold standard for Treatment-Resistant Schizophrenia (defined as persistent symptoms despite ≥ 2 \ge 2 ≥ 2 adequate trials of different antipsychotics, at least one being an SGA).

Canadian Clozapine Monitoring Network Protocol:

Major Life-Threatening Adverse Effect: Agranulocytosis (absolute neutrophil count [ANC] < 1.5 × 10 9 / L < 1.5 \times 10^9/L < 1.5 × 1 0 9 / L ).

Mandatory Laboratory Monitoring: Baseline Complete Blood Count (CBC) with differential, followed by weekly CBC for 6 months, biweekly for 6 months, then monthly thereafter.

Action Thresholds: If ANC drops below 1.5 × 10 9 / L 1.5 \times 10^9/L 1.5 × 1 0 9 / L (mild neutropenia), increase monitoring frequency. If ANC drops below 1.0 × 10 9 / L 1.0 \times 10^9/L 1.0 × 1 0 9 / L (severe neutropenia/agranulocytosis), Clozapine MUST BE IMMEDIATELY DISCONTINUED and re-challenge is contraindicated.

Other Clozapine Adverse Effects: Myocarditis/cardiomyopathy (check baseline troponin/ECG), severe constipation/paralytic ileus, sedation, hypersalivation (sialorrhea), seizures, weight gain.

  • Neurological & Psychiatric Emergencies
  • Extrapyramidal Symptoms (EPS) & Movement Disorders

Acute Dystonic Reaction:

Timing: Hours to days after starting or increasing high-potency FGA (e.g., Haloperidol).

Features: Sudden involuntary contraction of muscle groups (torticollis, trismus, oculogyric crisis , laryngospasm).

Treatment: Intramuscular (IM) Anticholinergics — Benztropine 1–2 mg IM or Diphenhydramine 25–50 mg IM.

Akathisia:

Timing: Days to weeks after initiating antipsychotics.

Features: Subjective feeling of inner restlessness and objective inability to sit still (pacing, rocking).

Treatment: Reduce antipsychotic dose, switch to SGA, or treat with Beta-blockers (Propranolol) or Benzodiazepines.

Parkinsonism:

Timing: Weeks to months after initiation.

Features: Tremor (pill-rolling), rigidity (cogwheel), bradykinesia, masked facies.

Treatment: Add oral Benztropine or Amantadine, or switch to an SGA with low D2 affinity (e.g., Quetiapine).

Tardive Dyskinesia (TD):

Timing: Months to years of chronic antipsychotic therapy.

Features: Involuntary choreoathetoid movements of face, lip smacking, tongue protrusion, trunk twisting.

Treatment: Discontinue offending agent if possible; switch to Clozapine or Quetiapine; treat with VMAT2 Inhibitors (Valbenazine, Deutetrabenazine). Anticholinergics worsen TD!

Neuroleptic Malignant Syndrome (NMS) vs. Serotonin Syndrome

HIGH-YIELD DIFFERENTIAL DIAGNOSIS TABLE:

Clinical Feature Neuroleptic Malignant Syndrome (NMS) Serotonin Syndrome (SS)

Causative Agents Antipsychotics (D2 antagonists, e.g., Haloperidol) Serotonergic agents (SSRIs, SNRIs, MAOIs, MDMA)

Onset Timeline Evolves over days to weeks Rapid onset within 24 hours

Neuromuscular Signs "Lead-pipe" generalized rigidity , hyporeflexia Hyperreflexia, clonus (inducible/spontaneous), tremor

Autonomic Signs High fever ( > 38.5 ∘ C >38.5^\circ\text{C} > 38. 5 ∘ C ), tachycardia, labile BP, diaphoresis Moderate fever, tachycardia, diaphoresis

  • Gastrointestinal Bowel sounds normal or decreased Hyperactive bowel sounds, diarrhea
  • Laboratory Marked elevation in Creatine Kinase (CK) & WBC Normal or mild CK elevation
  • Antidote / Treatment Stop dopamine blocker; Dantrolene or Bromocriptine Stop serotonergic; Cyproheptadine

Loading diagram... Schizophrenia Management & Medical Emergency Decision Matrix